Actelion, being bought by J&J, says full year profit rose 26 percent

Features Reuters

The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann (Copyright Reuters 2017)

Swiss drugmaker Actelion said on Tuesday that its full year 2016 net income rose 26 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension.

Continue Reading Below

Net income rose to 696 million Swiss francs ($693.4 million), lagging the average estimate of 737 million francs in a Reuters poll of analysts. Sales rose 18 percent to 2.42 billion francs, compared to the 2.41 billion francs expected in the poll.

(Reporting by John Miller; Editing by Michael Shields)